Document Detail


A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
MedLine Citation:
PMID:  22517037     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
T cell prolymphocytic leukemia (T-PLL) is a rare mature T cell lymphoproliferative disease. It has been associated with an aggressive course, a poor response to conventional chemotherapy and a short median survival. Here we present a rare case of concurrent T-PLL and Kaposi sarcoma who achieved a complete hematologic and cytogenetic remission after a very short course of treatment with alemtuzumab. A review of T-PLL was done. In this review, clinical features, laboratory features and current therapeutic strategies of T-PLL are presented.
Authors:
R N Paul; L Alizadeh; O I Ajayi; H Karpurapu; C Ganesan; L Taddesse-Heath; A Aggarwal
Related Documents :
21276157 - Fractionated co(2) laser skin rejuvenation.
16134437 - Assessing mortality rates from dubious data--when to stop doing statistics and start do...
19012627 - Two-year pilot study of newborn screening for congenital adrenal hyperplasia in new sou...
24345707 - Arthroscopic synovectomy, irrigation, and debridement for treatment of septic ankle art...
12792547 - Ball lightning burn.
1642777 - Chemical burns: our 10-year experience.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2012-04-13
Journal Detail:
Title:  Acta haematologica     Volume:  127     ISSN:  1421-9662     ISO Abbreviation:  Acta Haematol.     Publication Date:  2012  
Date Detail:
Created Date:  2012-05-15     Completed Date:  2012-07-11     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  235-43     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Division of Hematology/Oncology, Department of Medicine, Howard University Hospital, Washington, DC 20060, USA. rabipaul@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use
Antigens, CD
Antigens, Neoplasm
Antineoplastic Agents / therapeutic use
Glycoproteins / antagonists & inhibitors
Humans
Leukemia, Prolymphocytic, T-Cell / diagnosis,  immunology,  therapy*
Male
Neoplasms, Multiple Primary / diagnosis,  immunology,  therapy*
Remission Induction
Sarcoma, Kaposi / radiotherapy,  therapy*
Time Factors
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antigens, CD; 0/Antigens, Neoplasm; 0/Antineoplastic Agents; 0/CD52 antigen; 0/Glycoproteins; 3A189DH42V/alemtuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Parenteral amino acid intakes: possible influences of higher intakes on growth and bone status in pr...
Next Document:  Primary lateral sclerosis as progressive supranuclear palsy: diagnosis by diffusion tensor imaging.